BRPI0618484A2 - composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo Download PDF

Info

Publication number
BRPI0618484A2
BRPI0618484A2 BRPI0618484-7A BRPI0618484A BRPI0618484A2 BR PI0618484 A2 BRPI0618484 A2 BR PI0618484A2 BR PI0618484 A BRPI0618484 A BR PI0618484A BR PI0618484 A2 BRPI0618484 A2 BR PI0618484A2
Authority
BR
Brazil
Prior art keywords
mammal
compound
methods
salt
pharmaceutically acceptable
Prior art date
Application number
BRPI0618484-7A
Other languages
English (en)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Philip Arthur Hipskind
Jason Eric Lamar
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0618484A2 publication Critical patent/BRPI0618484A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INIBIR O RECEPTOR DE GLUCAGON EM UM MAMìFERO, PARA REDUZIR SELETIVAMENTE O NìVEL GLICêMICO EM UM MAMìFERO E PARA TRATAR DIABETE TIPO 2, E, USO DE UM COMPOSTO OU UM SAL DO MESMO. A presente invenção divulga os novos compostos da Fórmula i, ou os sais farmaceuticamente aceitáveis destes, os quais têm um antagonista do receptor de glucagon ou uma atividade agonista inversa, bem como aos métodos para preparar tais compostos. Em uma outra forma de realização, a invenção divulga as composições farmacêuticas que compreendem os compostos da Fórmula i bem como os métodos de usá-las para tratar um distúrbio diabético, outros distúrbios metabólicos relacionados com glucagon, e outros.
BRPI0618484-7A 2005-11-18 2006-11-10 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo BRPI0618484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73797905P 2005-11-18 2005-11-18
PCT/US2006/060769 WO2007114855A2 (en) 2005-11-18 2006-11-10 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
BRPI0618484A2 true BRPI0618484A2 (pt) 2011-08-30

Family

ID=38470878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618484-7A BRPI0618484A2 (pt) 2005-11-18 2006-11-10 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo

Country Status (12)

Country Link
US (1) US8076374B2 (pt)
JP (1) JP5100657B2 (pt)
CN (1) CN101309894B (pt)
AT (1) ATE473961T1 (pt)
AU (1) AU2006341392B2 (pt)
BR (1) BRPI0618484A2 (pt)
CA (1) CA2629321C (pt)
DE (1) DE602006015509D1 (pt)
DK (1) DK1951659T3 (pt)
ES (1) ES2346246T3 (pt)
PT (1) PT1951659E (pt)
WO (1) WO2007114855A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
US8361959B2 (en) 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
RU2013157388A (ru) * 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
JP2006500325A (ja) 2002-06-27 2006-01-05 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
WO2004056763A2 (en) * 2002-12-20 2004-07-08 Novo Nordisk A/S Novel glucagon antagonists
WO2004063147A1 (en) * 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
WO2005102067A1 (en) 2004-04-26 2005-11-03 Ipn Ip B.V. Packaged flowable ice product, such as a milk shake

Also Published As

Publication number Publication date
CA2629321A1 (en) 2007-10-11
AU2006341392B2 (en) 2012-05-17
CA2629321C (en) 2013-08-06
DE602006015509D1 (de) 2010-08-26
US20080319074A1 (en) 2008-12-25
ATE473961T1 (de) 2010-07-15
JP5100657B2 (ja) 2012-12-19
ES2346246T3 (es) 2010-10-13
PT1951659E (pt) 2010-09-10
AU2006341392A1 (en) 2007-10-11
JP2009519227A (ja) 2009-05-14
US8076374B2 (en) 2011-12-13
CN101309894B (zh) 2012-10-03
DK1951659T3 (da) 2010-10-11
CN101309894A (zh) 2008-11-19
WO2007114855A2 (en) 2007-10-11
WO2007114855A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
BRPI0607015A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BRPI0512058A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0514553A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
MX351656B (es) Antagonistas novedosos del receptor de glucagon.
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
EA201000926A1 (ru) Пиперазины в качестве агентов против ожирения
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2007034254A3 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.